AUA 2024
AUA 2024
Advertisement
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | May 21, 2024
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
View More
Patrick Soon-Shiong, MDNon-Muscle Invasive Urothelial Carcinoma | May 10, 2024
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Eric Li, MDProstate Cancer Diagnostics | May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Sarah Psutka, MD, MScRenal Cell Carcinoma Diagnostics | May 7, 2024
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Guru P. Sonpavde, MDAdvanced Urothelial Carcinoma | May 20, 2024
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Stephan Broenimann, MDUpper Tract Urothelial Carcinoma | May 7, 2024
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 6, 2024
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Emily MenendezRenal Cell Carcinoma | May 5, 2024
Approximately 82,000 new cases of RCC are diagnosed each year in the US, but effective early detection methods are lacking.
Yair Lotan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Yair Lotan, MDUpper Tract Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Philippe Spiess, MDTesticular, Penile, and Rare Malignancies | May 7, 2024
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
Yaw A. Nyame, MD, MS, MBAProstate Cancer Diagnostics | May 7, 2024
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
Katy MarshallAdvanced Urothelial Carcinoma | May 5, 2024
Researchers found increased OS and PFS benefits when patients received nivolumab plus gemcitabine.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 5, 2024
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
Seth Lerner, MD, FACSUpper Tract Urothelial Carcinoma | May 21, 2024
Dr. Lerner shares updates from the ENLIGHTED trial and analyses pertaining to NAC for UTUC from the ROBUUST registry.
Abhinav Khanna, MD, MPHRenal Cell Carcinoma Diagnostics | May 14, 2024
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
Zachary BessetteUpper Tract Urothelial Carcinoma | May 21, 2024
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Advertisement
Advertisement
Advertisement